103 related articles for article (PubMed ID: 9284849)
1. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans.
Boulton DW; Fawcett JP
Clin Pharmacol Ther; 1997 Aug; 62(2):138-44. PubMed ID: 9284849
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
Pulm Pharmacol Ther; 1999; 12(6):353-62. PubMed ID: 10587476
[TBL] [Abstract][Full Text] [Related]
4. Beta2-agonist eutomers: a rational option for the treatment of asthma?
Boulton DW; Fawcett JP
Am J Respir Med; 2002; 1(5):305-11. PubMed ID: 14720033
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
Jantikar A; Brashier B; Maganji M; Raghupathy A; Mahadik P; Gokhale P; Gogtay J; Salvi S
Respir Med; 2007 Apr; 101(4):845-9. PubMed ID: 17276051
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Lima JJ; Thomason DB; Mohamed MH; Eberle LV; Self TH; Johnson JA
Clin Pharmacol Ther; 1999 May; 65(5):519-25. PubMed ID: 10340917
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of levosalbutamol: what are the clinical implications?
Boulton DW; Fawcett JP
Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
[TBL] [Abstract][Full Text] [Related]
8. Human pharmacology of the methamphetamine stereoisomers.
Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective disposition of salbutamol in man following oral and intravenous administration.
Boulton DW; Fawcett JP
Br J Clin Pharmacol; 1996 Jan; 41(1):35-40. PubMed ID: 8824691
[TBL] [Abstract][Full Text] [Related]
10. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
Bennett JA; Tattersfield AE
Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Lipworth BJ; Clark DJ; Koch P; Arbeeny C
Thorax; 1997 Oct; 52(10):849-52. PubMed ID: 9404370
[TBL] [Abstract][Full Text] [Related]
12. Determination of bioavailability on the basis of tachycardia after intravenous and oral administration of fenoterol, orciprenaline and salbutamol in non-anaesthetized rats.
Muacevic G
Arzneimittelforschung; 1985; 35(1A):406-8. PubMed ID: 2859035
[TBL] [Abstract][Full Text] [Related]
13. Comparative cardiac toxicity of the i.v. administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs.
Schneider P; Güttner J; Eckenfels A; Heinzel G; von Nicolai H; Trieb G; Lehmann H
Exp Toxicol Pathol; 1997 Aug; 49(3-4):217-24. PubMed ID: 9314056
[TBL] [Abstract][Full Text] [Related]
14. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol.
Dhand R; Goode M; Reid R; Fink JB; Fahey PJ; Tobin MJ
Am J Respir Crit Care Med; 1999 Oct; 160(4):1136-41. PubMed ID: 10508799
[TBL] [Abstract][Full Text] [Related]
15. An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies.
García-Arieta A; Abad-Santos F; Rodríguez-Martínez MA; Varas-Polo Y; Novalbos J; Laparidis N; Gallego-Sandín S; Orfanidis K; Torrado J
Chirality; 2005 Oct; 17(8):470-5. PubMed ID: 16104026
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.
Lötvall J; Palmqvist M; Arvidsson P; Maloney A; Ventresca GP; Ward J
J Allergy Clin Immunol; 2001 Nov; 108(5):726-31. PubMed ID: 11692096
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers.
Du XL; Zhu Z; Fu Q; Li DK; Xu WB
Acta Pharmacol Sin; 2002 Jul; 23(7):663-6. PubMed ID: 12100764
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.
Hochhaus G; Möllmann H
Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):342-62. PubMed ID: 1358833
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.
Milgrom H; Skoner DP; Bensch G; Kim KT; Claus R; Baumgartner RA;
J Allergy Clin Immunol; 2001 Dec; 108(6):938-45. PubMed ID: 11742271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
